

# Iain A Mcneish

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6887303/publications.pdf>

Version: 2024-02-01

172  
papers

19,745  
citations

34016

52  
h-index

11899

134  
g-index

187  
all docs

187  
docs citations

187  
times ranked

32468  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	6.3	1,261
3	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
4	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	5.1	975
5	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
6	Re-educating tumor-associated macrophages by targeting NF- $\kappa$ B. <i>Journal of Experimental Medicine</i> , 2008, 205, 1261-1268.	4.2	700
7	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	0.6	665
8	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	13.9	651
9	A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor. <i>Clinical Cancer Research</i> , 2006, 12, 6737-6747.	3.2	514
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
11	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6083-6096.	3.2	330
12	Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. <i>International Journal of Cancer</i> , 2010, 126, 2762-2772.	2.3	321
13	Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018, 50, 1262-1270.	9.4	320
14	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	7.7	310
15	Mannose impairs tumour growth and enhances chemotherapy. <i>Nature</i> , 2018, 563, 719-723.	13.7	282
16	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	7.7	278
17	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic <i>BRCA1</i> or <i>BRCA2</i> mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	0.6	222
18	Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck. <i>Clinical Cancer Research</i> , 2010, 16, 4005-4015.	3.2	217

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3798-3804.	0.8	203
20	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	5.8	192
21	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology</i> , The, 2018, 19, 1680-1687.	5.1	187
22	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	1.2	167
23	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
24	CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Research</i> , 2016, 76, 6118-6129.	0.4	145
25	Survivin: A Protein with Dual Roles in Mitosis and Apoptosis. <i>International Review of Cytology</i> , 2005, 247, 35-88.	6.2	143
26	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 2084-2095.	6.3	142
27	Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 4862-4866.	0.8	137
28	Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. <i>International Journal of Cancer</i> , 2007, 120, 2344-2352.	2.3	126
29	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€“MONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964.	0.8	125
30	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3025-3036.	3.2	124
31	Activating a collaborative innate-adaptive immune response to control metastasis. <i>Cancer Cell</i> , 2021, 39, 1361-1374.e9.	7.7	122
32	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
33	Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. <i>Cell Reports</i> , 2020, 30, 481-496.e6.	2.9	111
34	Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells. <i>Molecular and Cellular Biology</i> , 2003, 23, 7600-7610.	1.1	105
35	Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors. <i>Viruses</i> , 2010, 2, 2290-2355.	1.5	104
36	Twenty-five years' clinical experience with placental site trophoblastic tumors. <i>Journal of reproductive medicine</i> , The, 2002, 47, 460-4.	0.2	104

#	ARTICLE	IF	CITATIONS
37	Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis. <i>Cancer Immunology Research</i> , 2020, 8, 1099-1111.	1.6	90
38	Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1240-1250.	0.6	85
39	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. <i>Nature Communications</i> , 2017, 8, 14206.	5.8	81
40	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
41	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	0.6	74
42	Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. , 2000, 86, 848-854.		71
43	CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. <i>Scientific Reports</i> , 2017, 7, 16827.	1.6	68
44	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 276-287.	0.6	68
45	Targeted anti-vascular therapies for ovarian cancer: current evidence. <i>British Journal of Cancer</i> , 2013, 108, 250-258.	2.9	64
46	Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. <i>Gynecologic Oncology</i> , 2016, 141, 195-198.	0.6	60
47	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. <i>Cell Reports</i> , 2021, 36, 109412.	2.9	60
48	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5508-5508.	0.8	60
49	In Vivo Retargeting of Adenovirus Type 5 to $\alpha_6\beta_1$ Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery. <i>Journal of Virology</i> , 2009, 83, 6416-6428.	1.5	59
50	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. <i>Current Biology</i> , 2016, 26, 755-765.	1.8	57
51	Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 3317-3327.	0.4	56
52	The peritoneal tumour microenvironment of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2012, 227, 136-145.	2.1	54
53	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
54	Management of brain metastases in patients with high-risk gestational trophoblastic tumors. <i>Journal of reproductive medicine, The</i> , 2002, 47, 465-71.	0.2	54

#	ARTICLE	IF	CITATIONS
55	Activity of the Adenoviral E1A Deletion Mutant dl922-947 in Ovarian Cancer: Comparison with E1A Wild-type Viruses, Bioluminescence Monitoring, and Intraperitoneal Delivery in Icodextrin. <i>Cancer Research</i> , 2006, 66, 989-998.	0.4	53
56	Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells. <i>Molecular Therapy</i> , 2013, 21, 2074-2086.	3.7	52
57	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.4	49
58	Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. <i>Annals of Oncology</i> , 2017, 28, 702-710.	0.6	46
59	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	1.1	44
60	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	3.4	44
61	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
62	Nuclear Survivin Abrogates Multiple Cell Cycle Checkpoints and Enhances Viral Oncolysis. <i>Cancer Research</i> , 2008, 68, 7923-7931.	0.4	41
63	Targeting DNA repair: the genome as a potential biomarker. <i>Journal of Pathology</i> , 2018, 244, 586-597.	2.1	41
64	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENAâ€‘MONO) and rucaparib in combination with nivolumab (ATHENAâ€‘COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1589-1594.	1.2	40
65	Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. <i>Oncogene</i> , 2003, 22, 3539-3547.	2.6	38
66	Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Testâ€‘Retest Measurements for Tumor FDG Uptake, Diameter, and Volume. <i>Clinical Cancer Research</i> , 2014, 20, 2751-2760.	3.2	38
67	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11217.	3.3	37
68	Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. <i>Cell Death and Differentiation</i> , 2001, 8, 256-264.	5.0	36
69	Clear Cell Carcinoma of Ovary and Uterus. <i>Current Oncology Reports</i> , 2013, 15, 566-572.	1.8	36
70	Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1377-1385.	3.3	35
71	Oncolytic virus-induced cell death and immunity: a match made in heaven?. <i>Journal of Leukocyte Biology</i> , 2017, 102, 631-643.	1.5	35
72	Oncologist-led BRCA â€‘mainstreamingâ€™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. <i>Scientific Reports</i> , 2020, 10, 3390.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 277-288.	5.1	34
74	Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2. <i>Gynecologic Oncology</i> , 2017, 145, 2.	0.6	33
75	Proinflammatory Characteristics of SMAC/DIABLO-Induced Cell Death in Antitumor Therapy. <i>Cancer Research</i> , 2012, 72, 1342-1352.	0.4	32
76	Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. <i>Clinical Cancer Research</i> , 2002, 8, 1142-7.	3.2	31
77	Failure of Translation of Human Adenovirus mRNA in Murine Cancer Cells Can be Partially Overcome by L4-100K Expression In Vitro and In Vivo. <i>Molecular Therapy</i> , 2012, 20, 1676-1688.	3.7	30
78	Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 161-168.	1.2	30
79	Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer. <i>Oncotarget</i> , 2012, 3, 78-83.	0.8	30
80	NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 289-301.	2.0	29
81	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	1.1	28
82	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. <i>Molecular Oncology</i> , 2015, 9, 791-805.	2.1	27
83	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. <i>Clinical Cancer Research</i> , 2017, 23, 7633-7640.	3.2	27
84	Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214.	3.2	27
85	The Emerging Role of Interleukin 1 $\beta$ (IL-1 $\beta$ ) in Cancer Cachexia. <i>Inflammation</i> , 2021, 44, 1223-1228.	1.7	27
86	Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and $^3\text{H}$ -Deoxy- $^3\text{H}$ -[18F]Fluorothymidine Positron Emission Tomography Imaging. <i>Cancer Research</i> , 2006, 66, 9178-9185.	0.4	25
87	Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. <i>Journal of Clinical Investigation</i> , 2011, 121, 1283-1297.	3.9	25
88	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5540-5540.	0.8	25
89	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	1.3	24
90	Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. <i>International Journal of Cancer</i> , 2003, 104, 104-112.	2.3	23

#	ARTICLE	IF	CITATIONS
91	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	2.9	23
92	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 969-977.	5.1	23
93	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
94	Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. , 2021, 9, e003645.		23
95	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 4722-4736.	0.8	22
96	Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. <i>FASEB Journal</i> , 2013, 27, 4244-4253.	0.2	21
97	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021, 100, 102294.	3.4	21
98	A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 808-810.	1.1	20
99	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017, 28, 459-468.	0.8	20
100	Organoid models in gynaecological oncology research. <i>Cancer Treatment Reviews</i> , 2020, 90, 102103.	3.4	20
101	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	1.6	20
102	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	0.6	20
103	Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 522-534.	1.9	20
104	Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. <i>Gene Therapy</i> , 2015, 22, 476-484.	2.3	19
105	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i> -mutated, high-grade ovarian cancer, and an update on safety. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1396-1404.	1.2	19
106	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2911-2922.	3.2	19
107	Inhibition of the Inflammatory Cytokine TNF- $\alpha$ Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 Expression. <i>Molecular Therapy</i> , 2011, 19, 490-499.	3.7	18
108	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18

#	ARTICLE	IF	CITATIONS
109	p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. <i>Molecular Cancer</i> , 2010, 9, 175.	7.9	16
110	RIPK3 promotes adenovirus type 5 activity. <i>Cell Death and Disease</i> , 2017, 8, 3206.	2.7	16
111	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	0.6	15
112	RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 44-55.	1.5	15
113	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	0.9	15
114	Visualization of cardiac emboli from mitral valve papillary fibroelastoma. <i>Stroke</i> , 1996, 27, 1133-4.	1.0	14
115	The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. <i>Biomaterials</i> , 2011, 32, 8538-8547.	5.7	13
116	Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. <i>British Journal of Cancer</i> , 2017, 116, 1294-1301.	2.9	13
117	BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1. <i>Gynecologic Oncology</i> , 2017, 145, 5.	0.6	13
118	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	0.8	13
119	2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. <i>European Journal of Cancer</i> , 2015, 51, S531-S532.	1.3	12
120	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	1.1	12
121	Prophylactic <i>In Vivo</i> Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models. <i>Cancer Research</i> , 2020, 80, 549-560.	0.4	12
122	Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2009, 116, 1225-1241.	1.1	11
123	Pharmacological Inhibition of $\beta_3$ Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. <i>Cancer Research</i> , 2015, 75, 2811-2821.	0.4	11
124	7220 Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA). <i>Annals of Oncology</i> , 2021, 32, S725-S726.	0.6	11
125	Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 5549-5549.	0.8	11
126	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2022, 23, 919-930.	5.1	11



#	ARTICLE	IF	CITATIONS
127	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	1.1	9
128	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092198.	1.4	8
129	Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. <i>Oncogene</i> , 2021, 40, 3665-3679.	2.6	8
130	Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5530-5530.	0.8	8
131	Metronomic oral cyclophosphamide in relapsed ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1037-1044.	1.2	8
132	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5619-TPS5619.	0.8	8
133	Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature. <i>Cancers</i> , 2022, 14, 2708.	1.7	8
134	Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. <i>Future Oncology</i> , 2009, 5, 339-357.	1.1	7
135	Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial. <i>Gynecologic Oncology</i> , 2015, 138, 4.	0.6	7
136	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824.	1.2	7
137	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	0.6	7
138	Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. <i>Viruses</i> , 2021, 13, 1450.	1.5	7
139	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019, 8, 200.	1.8	6
140	Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	5
141	OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer Vistusertib (AZD2014).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5609-TPS5609.	0.8	4
142	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	1.1	3
143	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	1.8	3
144	ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5611-TPS5611.	0.8	3

#	ARTICLE	IF	CITATIONS
145	NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium.. Journal of Clinical Oncology, 2016, 34, TPS5603-TPS5603.	0.8	3
146	Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo. International Journal of Molecular Medicine, 2006, 17, 841-7.	1.8	3
147	IL-6 and Ovarian Cancerâ€™Response. Clinical Cancer Research, 2011, 17, 7838-7838.	3.2	2
148	Preliminary Results of Ariel2, a Phase 2 Open-Label Study to Identify Ovarian Cancer Patients Likely to Respond to Rucaparib. Annals of Oncology, 2014, 25, iv308.	0.6	2
149	Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). European Journal of Cancer, 2017, 72, S95.	1.3	2
150	Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?. Clinical Cancer Research, 2018, 24, 5493-5495.	3.2	2
151	8050 ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology, 2020, 31, S610.	0.6	2
152	FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. JCO Clinical Cancer Informatics, 2021, 5, 176-186.	1.0	2
153	A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.. Journal of Clinical Oncology, 2015, 33, TPS5611-TPS5611.	0.8	2
154	A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I.. Journal of Clinical Oncology, 2016, 34, 5543-5543.	0.8	2
155	Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.. Journal of Clinical Oncology, 2018, 36, 5545-5545.	0.8	2
156	Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data. SSRN Electronic Journal, 0, , .	0.4	2
157	Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers. ESMO Open, 2022, 7, 100401.	2.0	2
158	ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology, 2016, 27, vi297.	0.6	1
159	Progression-free survival in the ICON8 trial â€™ Authors' reply. Lancet, The, 2020, 396, 757.	6.3	1
160	TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.. Journal of Clinical Oncology, 2016, 34, TPS5604-TPS5604.	0.8	1
161	A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.. Journal of Clinical Oncology, 2017, 35, 2594-2594.	0.8	1
162	Author response to: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 1586-1587.	1.1	0

#	ARTICLE	IF	CITATIONS
163	Author response to: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 1714-1714.	1.1	0
164	Oncolytic viral gene therapy in ovarian cancer. , 0, , 139-152.		0
165	Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and therapeutics. , 0, , 245-248.		0
166	Role of innate immune responses in the effectiveness of oncolytic adenovirus as an anticancer agent. <i>Lancet, The</i> , 2017, 389, S61.	6.3	0
167	Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5539-5539.	0.8	0
168	Routine germline BRCA testing in serous ovarian cancer: The West of Scotland experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16532-e16532.	0.8	0
169	Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.. , 2016, , .		0
170	44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, S400-S401.	0.6	0
171	ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5617-TPS5617.	0.8	0
172	Response to the letter entitled "Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers" ESMO Open, 2022, 7, 100534.	2.0	0